Mechanism
NAD+ is one of the most fundamental molecules in metabolism — that part is not controversial. The open questions are whether flooding the body with it meaningfully raises functional NAD+ where it matters, and whether that translates into the outcomes people are sold.
| Mechanism | Detail |
|---|---|
| Redox currency | NAD+ and its reduced form NADH shuttle electrons through energy metabolism. Without it, cells cannot turn food into ATP — hence the “energy” framing. Levels are thought to decline with age. |
| Sirtuin fuel | Sirtuins are NAD+-dependent enzymes tied to DNA repair and mitochondrial function. Much of the longevity story rests on more NAD+ → more sirtuin activity — a chain that is cleaner in mice than in people. |
| PARP & CD38 consumption | DNA-repair enzymes (PARPs) and the ectoenzyme CD38 consume NAD+; CD38 rises with age and inflammation, draining the pool. Some argue the problem is consumption, not just supply. |
| The bioavailability question | Injected NAD+ is a large, charged molecule that likely does not cross cell membranes intact — it is thought to be broken down to precursors and rebuilt. If so, an IV drip and an oral precursor may converge on a similar pathway. |
Evidence Summary
Here the gap between story and data is wide. NAD+ biology is real and important; the claims sold in clinics — reverse aging, restore energy, cure addiction — are mostly extrapolated from animal work or precursor trials measuring surrogate markers, not injected NAD+ measuring hard outcomes.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| Raising NAD+ levels | Oral NMN/NR raise NAD+ markers | Human RCTs (precursors) | The one well-established thing — but a biomarker, not a benefit. |
| Metabolic markers | Small, inconsistent effects | Meta-analysis (precursors) | Modest and heterogeneous, not the transformation implied by marketing. |
| Energy & fatigue | Uncontrolled “more energy” reports | Anecdote / open-label | Clinic experience, not blinded trials. |
| Longevity / anti-aging | Mouse data only | Preclinical | No human trial demonstrates slowed aging. |
| Addiction / recovery | Heavily promoted, little support | Anecdote | One of the biggest evidence-to-hype gaps in this space. |
| Cognition & muscle | Mixed small precursor trials | Small RCTs (precursors) | Underpowered and short; hard to draw conclusions. |
| Human clinical trials (injected NAD+) | Scarce on meaningful outcomes | Human | The product sold in clinics is the least-studied form. |
Divergence — What This Means
Clinic hype versus the data.
IV NAD+ drips are marketed for energy, longevity, and addiction recovery at premium prices, backed largely by testimonials and mechanism — not outcome trials. The strongest human evidence is for oral precursors (NMN/NR) raising a blood marker, and infused NAD+ may simply be broken down to those same precursors anyway.
A quieter source of confusion is conflation: “NAD+” is used loosely to mean the coenzyme, the IV therapy, and the oral precursors interchangeably, so a positive NMN study gets cited to sell an IV drip. Important molecule, thin outcome evidence for the injected product.
A quieter source of confusion is conflation: “NAD+” is used loosely to mean the coenzyme, the IV therapy, and the oral precursors interchangeably, so a positive NMN study gets cited to sell an IV drip. Important molecule, thin outcome evidence for the injected product.
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
IV infusion (clinic)
250–1000 mg
per session; slow infusion over hours
Infusion rate
Rate-limited
slowed to control flushing/nausea
SC injection (community)
~50–100 mg
self-reported; not standardized
Oral precursors
NMN/NR 250–1000 mg/d
the better-studied route
There is no established therapeutic dose for injected NAD+ — ranges reflect clinic practice and community reports, not validated protocols. Fast IV infusion is the main driver of acute discomfort. RUO; not medical advice.
Safety Profile
Short-term tolerability of slow IV NAD+ appears reasonable in small real-world reports, but effects are dose- and rate-dependent and long-term data are essentially absent.
Animal / preclinical — signals observed
Flushing, warmth, and facial redness during infusion
Nausea and abdominal cramping — worse with fast infusion
Chest tightness or lightheadedness if run too quickly
Injection-site discomfort with SC use
What is not known (human)
Whether injected NAD+ enters cells intact or acts only via precursors
Long-term safety of repeated high-dose infusions
Any effect on hard clinical or longevity outcomes in humans
Safety in people with cardiovascular disease, pregnancy, or on medications
Purity and dosing consistency of RUO / compounded sources
Most tolerability signals come from small, uncontrolled clinic settings. Absence of reported harm is not the same as proven long-term safety.
Regulatory Status — Updated July 2026
Not part of the July 2026 PCAC review
NAD+ was not among the substances evaluated in the July 2026 PCAC review, so no new committee recommendation applies to it. In practice, injectable NAD+ is used in some clinics and sold research-use-only, while oral precursors (NMN and NR) are marketed as dietary supplements. None of these is an FDA-approved drug, and status can shift. Track current status →
Where to Source
Source research-grade NAD+
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source NAD+.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
No. NAD+ is a coenzyme (a pyridine dinucleotide) built from nicotinamide and adenine, not a chain of amino acids. It is covered here because it is sold and injected in the same peptide-adjacent longevity market.
NAD+ is the active coenzyme itself. NMN and NR are precursors your body uses to build NAD+. Most of the better human data is on the oral precursors, not on injected NAD+ — and injected NAD+ may itself be broken down into precursors before use. They are often marketed as if interchangeable.
Not on current evidence. Benefits are shown in mice, and NAD+ declines with age in humans — but no human trial has demonstrated that raising NAD+ slows or reverses aging. The anti-aging claim is an extrapolation, not a proven outcome.
It is heavily marketed for withdrawal and cravings, often as “brain restoration,” but there is essentially no robust randomized evidence supporting it. Reported benefits are anecdotal and uncontrolled. Treat strong claims here with particular skepticism.
Compare NAD+